Hepatitis C infection: Eligibility for antiviral therapies

European Journal of Gastroenterology and Hepatology

Volumn 17, Issue 11, 2005, Pages 1185-1189

  Delwaide, Jean ^a,b   El Saouda, Refaat ^a   Gérard, Christiane ^a,b   Belaïche, Jacques ^a,b   De Roover, Arnaud ^b   Detry, Olivier ^b   Honoré, Pierr̀e ^b   Maggipinto, Gianni ^b   Meurisse, Michel ^b   Rentier, Bernard ^b   Vaira, Dolorès ^b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Adverse events; Contraindication; Cost; Epidemiology; Hepatitis C; Interferon alfa; Treatment

Indexed keywords

AMINOTRANSFERASE; ANTIVIRUS AGENT; PEGINTERFERON; RIBAVIRIN;

ADULT; BLOOD TRANSFUSION; CAUCASIAN; DATA BASE; DRUG RESPONSE; DRUG USE; EVALUATION; FEMALE; GENOTYPE; HEART; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; MENTAL DISEASE; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIDE EFFECT; TREATMENT CONTRAINDICATION; VIREMIA;

ADULT; ANTIVIRAL AGENTS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; PATIENT SELECTION; RISK FACTORS; TRANSAMINASES; TREATMENT OUTCOME; TREATMENT REFUSAL;

EID: 27344454220     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200511000-00006     Document Type: Review

References (26)

1. Alter MJ, Kruszon-Moran D, Nainan O, McQuillan G, Gao F, Moyer L, et al. The presence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341:556-562.
2. Van Damme P, Vellinga A. Epidemiology of hepatitis B and C in Europe. Acta Gastroenterol Belg 1998; 61:175-182.
3. Beutels M, Van Damme P, Aelvoet W, Desmyter J, Dondeyne F, Goilav C, et al. Prevalence of hepatitis A, B, and C in the Flemish population. Eur J Epidemiol 1997; 13:275-280.
4. Foster G, Goldin R, Thomas H. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998; 27:209-212.
5. Strader D, Wright T, Thomas D, Seef L. Diagnosis, management, and treatment of hepatitis C. AASLD practice guideline. Hepatology 2004; 39:1147-1171.
6. Sullivan S, Jensen D, Bernstein D, Hassanein T, Foster G, Lee S, et al. Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C. Am J Gastroenterol 2004; 99:1490-1496.
7. Buti M, Medina M, Casado M, Wong J, Fosbrook L, Esteban R. A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C. Aliment Pharmacol Ther 2003; 17:687-694.
8. Siebert U, Sroczynski G, Rossol S, Wassem J, Ravens-Sieberer U, Kurth B, et al. Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 2003; 52:425-432.
9. Wong J, Nevens F. Cost-effectiveness of peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin as initial treatment of chronic hepatitis C in Belgium. Acta Gastroenterol Belg 2002; 65:110-111.
10. Annemans L, Warie H, Nechelput M, Peraux B. A health economic model to assess the long term effects and cost-effectiveness of peginterferon alpha-2a in hepatitis C virus infected patients. Acta Gastroenterol Belg 2004; 67:1-8.
11. Delwaide J. Economic evaluation of chronic hepatitis C treatment by interferon-ribavirin combination therapy in Belgium. Acta Gastroenterol Belg 2002; 65:233-236.
12. Muir A, Provenzale D. A descriptive evaluation of eligibility for therapy among Veterans with chronic hepatitis C virus infection. J Clin Gastroenterol 2002; 34:268-271.
13. Rowan P, Tabasi S, Abdul-Iatif M, Kunik M, ElSerag H. Psychosocial factors are the most common contraindications for antiviral therapy at initial evaluation in Veterans with chronic hepatitis C. J Clin Gastroenterol 2004; 38:530-534.
14. Hu KQ, Lin YC, Yang H, McCracken J, Tyler D, Patel S, et al. Clinical profile of chronic hepatitis C in US Veterans in comparison with non-Veterans [Abstract]. Hepatology 2000; 32 (suppl):280A.
15. Falck-Ytter Y, Kale H, Mullen K, Sarbah S, Sorescu L, McCullough A. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 2002; 136:288-292.
16. Shad J, Person J, Brann O, Moon S, Pockros P, Nyberg L, et al. How often are referred chronic hepatitis C patients eligible for antiviral therapy? [Abstract]. Hepatology 2000; 32 (suppl):283A.
17. Rocca LG, Yawn B, Wollan P, Ray Kim W. Management of patients with hepatitis C in a community population: diagnosis, discussions, and decisions to treat. Ann Fam Med 2004; 2:116-124.
18. Gérard C, Delwaide J, Vaira D, Bastens B, Servais B, Wain E, et al. Evolution over a 10 years period of the epidemiological profile of 1,726 newly diagnosed HCV patients in Belgium. J Med Virol 2005; 76:503-510.
19. Manns M, McHutchison J, Gordon S, Rustgi V, Shiftman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358:958-965.
20. Fried M, Shiftman M, Reddy K, Smith C, Marinos G, Goncales F, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
21. Hadziyannis S, Sette H, Morgan T, Balan V, Diago M, Marcellin P, et al. Peginterferon alfa-2a and ribavirin combination therapy in chronic hepatitis C. A randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346-355.
22. Martinot-Peignoux M, Roudot-Thoroval F, Mendel I, Coste J, Izopet J, Duverlie G, et al. Hepatitis C virus genotypes in France: relationship with epidemiology, pathogenicity, and response to interferon therapy. J Viral Hepatol 1999; 6:435-443.
23. Roudot-Thoraval F, Bastie A, Pawlotsky JM, Dhumeaux D, and the Study Group for the Prevalence and the Epidemiology of Hepatitis C Virus. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6,664 patients. Hepatology 1997; 26: 485-490.
24. Zeuzem S, Diago M, Gane E, Reddy R, Pockros P, Prati D, et al. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 2004; 127:1724-1732.
25. Jensen D, Cotler S, Lam H, Harb G, Shillington A. A comparison of hepatitis C treatment and outcomes at academic, private and Veterans' Affairs treatment centres. Aliment Pharmacol Ther 2004; 19:69-77.
26. National Institutes of Health: National Institutes of Health Consensus Development Conference Statement: management of hepatitis C: 2002. Hepatology 2002; 36 (suppl 1):S3-S20.